ArticlePloS one2025
Study on the quantitative analysis of Tilianin based on Raman spectroscopy combined with deep learning.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tilianin is a commonly used pharmaceutical ingredient with various biological activities such as antioxidant, anti-inflammatory, and anticancer, which is able to exert antitumor effects by inhibiting tumor cell proliferation, inducing apoptosis and inhibiting angiogenesis. Studies have demonstrated to be particularly useful in a variety of cancers such as liver, lung and gastric cancers. Quantitative analysis of Tilianin can improve the quality control of related drugs and assist in guiding clinical application and disease treatment. However, there are limited studies on the quantitative analysis of Tilianin. High performance liquid chromatography (HPLC) and mass spectrometry (MS) are commonly used methods for the quantitative analysis of the components, but they often require complex pretreatment steps and specialized analytical capabilities, and are sample-destructive. The method based on Raman spectroscopy and deep learning is a widely used non-destructive analysis method. For this reason, this paper proposes a residual self-attention mechanism model based on Raman spectroscopy and deep learning for quantitative analysis of 6 concentrations of Tilianin. Six different concentrations of Tilianin-methanol solutions were prepared, and a total of 120 spectral samples were collected, which were pre-processed and inputted into our Raman Spectrum with Self-Attention Quantification Net (RSAQN) for analyzing and predicting. The structure of this model not only focuses on the deep and shallow features of the spectrum, but also the information between different channels, and the self-attention mechanism further extracts the features and outputs the predicted values of Tilianin concentration through the fully connected layer. In this paper, five sets of comparison models are set up, including two machine learning models (Random Forest, K-Nearest Neighbors, Artificial Neural Network) and two deep learning models (Convolutional Neural Network and Variational Autoencoder), and the results show that the model in this paper fits the best, obtaining an R2 of 0.9144, as well as a small error.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.